December 11th-13th 2019 “In addition, we are very pleased to announce that we will showcase our products and services at our booth in the Las Vegas Cannabis MJBizCon show this December 11-13, 2019.” https://www.otcmarkets.com/stock/EBYH/news/Strainsforpains-Inc-Provides-Shareholder-Update?id=233949 Cannibis Strain App Authorized Shares
550,000,000 07/31/2019
Outstanding Shares
10,588,356 07/31/2019
Restricted
10,306,359 07/31/2019
Unrestricted
281,997 07/31/2019
Held at DTC
198,844 07/31/2019
"Company will showcase APP design and Demo. APP to follow."
Doctors Access
Doctors WILL now have access to decision making tools which lessens their reliance on experimentation and guesswork, and improves their confidence in consistent and personalized cannabis treatments.
Patients Access To APP
The company expects a BETA launch to happen by the end of 2nd Q of 2018. It should result in thousands of new social media followers and newsletter subscribers, dozens of strategic partnerships and qualified investor leads, and feature stories
Dispensary Access To Data
Our industry specific, cloud-based platform s being developed with robust artificial intelligence and data mining capabilities, positioning the company as the WebMD of the cannabis industry.
Natural Medicine
We seek to fill that need by creating the industry standard for cannabis-related advice, selection, terminology, and data, all without touching the actual plant – enabling the Company to work in any regulatory environment.
Dr. Michael Stern MD
Dr. Michael Stern graduated from medical school in 1973 and since 1983 has been a board-certified urologist and urological surgeon. Dr. Stern served as an adjunct clinical faculty member at Bast-yr University School of Naturopathic Medicine for 11 years (1995 --2006). Dr. Stern owned the Northwest Healthy Options Clinic in Seattle, Washington. Dr. Stern continues advising patients on lifestyle issues and alternative healthy treatments for a wide variety of diseases, including medical cannabis.
Dr. Bindiya Moorjani , Neuroscientist
Dr. Bindiya Moorjani was a awarded a Ph. D. in biomedical sciences from the Fishberg Research Center for Neurobiology, Mount Sinai School of Medicine, New York University. Dr. Moorjani has authored several scientific studies that have been published in scientific journals. She did major studies on Serotonin.
From 1993 through 1999, Dr. Moorjani was a graduate researcher at the Mount Sinai School of Medicine in the doctoral program concentrating on neurobiology.